Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Miglustat crossover study of nasal potential difference in cystic fibrosis with homozygous F508del mutation
2008-002352-20Phase 2Completed
- Sponsor
- Actelion Pharmaceuticals Ltd
- Start
- Jul 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of miglustat in cystic fibrosis (CF) (2 arms), sponsored by Actelion Pharmaceuticals Ltd. Primary endpoint: Change in total chloride secretion on nasal potential difference. Started Jul 2008; status: completed.
02
Drugs
miglustat
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on 2008-002352-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-002352-20.